ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Main objective: To determine the optimal molar doses of the biospecific antibody TF2 and 68
Ga-IMP-288 and the optimal time for pretargeting for immuno-PET in patients with breast
carcinoma.
Secondary objectives: To study the sensitivity of the immuno-PET, compare its performance to
standard imaging methods, evaluate the safety of 150 MBq of 68 Ga-IMP-288; study the
development of immunization against TF2 or complex TF2-IMP-288;